Imatinib
- PDF / 123,081 Bytes
- 1 Pages / 623.591 x 841.847 pts Page_size
- 34 Downloads / 198 Views
1
Imatinib Periorbital oedema in an elderly patient: case report A 70-year-old man developed periorbital oedema while receiving imatinib for chronic myeloid leukaemia. The man started receiving imatinib [Gleevec] 400 mg/day. Within 2 weeks, he developed mild periorbital oedema. Three months later, his imatinib dosage was increased to 600 mg/day. His periorbital oedema significantly worsened and became visually disruptive. The man received conservative therapy, including a low-salt diet, restricted fluid intake, elevation of the head of his bed, and hydrocortisone cream. His symptoms did not respond. Subsequently, he was referred for bilateral lower and upper eyelid blepharoplasty. At his first examination, his visual acuity was 20/25 OD and 20/40 OS. His intraocular pressure was 18mm Hg in both eyes. The anterior septal tissue of his lower and upper eyelids was markedly distended. He had a visually disruptive superior field defect. After his eyelids were bilaterally taped, the defect disappeared. He reported a functional field defect, which was definitively treated with bilateral lower and upper eyelid blepharoplasty. After the operation, he required a blood transfusion for extensive bleeding. Light microscopy confirmed a diagnosis of marked periorbital oedema associated with imatinib. He continued to receive imatinib. Seventeen months after blepharoplasty, he was still receiving imatinib 600 mg/day, with no recurrence of periorbital oedema. Melicher Larson JS, et al. Severe periorbital edema secondary to imatinib mesylate for chronic myelogenous leukemia. Archives of Ophthalmology 125: 985-986, No. 801091723 7, Jul 2007 - USA
0114-9954/10/1173-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Reactions 13 Oct 2007 No. 1173
